Products

EyeBOX
Oculogica
Clinical Decision Support & Reference
EyeBOX by Oculogica is the first FDA-cleared, AI-powered eye-tracking device for objective, baseline-free concussion diagnosis and recovery monitoring in patients aged 5-67, delivering results in under 4 minutes.

See all 1 product →

About Oculogica

Oculogica is a neurodiagnostic company at the forefront of healthcare AI, specializing in objective brain health assessment through advanced eye-tracking technology. Their flagship product, EyeBOX, is an FDA-cleared device designed to aid in the diagnosis of concussion, also known as mild traumatic brain injury (mTBI), in patients aged 5 to 67. The EyeBOX system utilizes proprietary software and infrared cameras to track over 100,000 eye movement data points while a patient watches a short, 220-second video. This innovative approach allows for a rapid, non-invasive, and objective assessment of cranial nerve function and subtle ocular behaviors, generating a quantifiable ‘BOX score’ without the need for pre-injury baseline data or subjective patient input.

For physicians, EyeBOX offers a transformative tool to overcome the challenges of subjective concussion diagnosis, which often relies heavily on patient history and clinical judgment. By providing objective data, EyeBOX can help clinicians quickly and accurately rule in or rule out a concussion, facilitating earlier and more appropriate treatment. This technology is particularly valuable in emergency, sports medicine, and pediatric settings, where speed, accessibility, and language independence are crucial. Beyond concussion, Oculogica is also exploring the application of its eye-tracking technology for detecting traumatic brain injury (TBI), studying chronic traumatic encephalopathy (CTE), and has introduced OcuPro, a roadside cannabis impairment test.

Focus Areas

Concussion diagnosis traumatic brain injury (TBI) detection eye-tracking technology neurodiagnostics objective neurological assessment

Business Intelligence

Key InvestorsTitletownTech, GHS Investment Management (Canada) Company, Highcroft Capital, US Army Medical Research and Development Command, Colle Capital Partners, FIN Capital Angels, Golden Seeds
PartnershipsTitletownTech, US Army Medical Research and Development Command (USAMRDC), Keller Army Hospital at West Point, Children's Hospital of Philadelphia, University of Wisconsin-Green Bay, AdHawk Microsystems, XcelABLE, The Geneva Foundation
AcquisitionsNone
TechnologyEye-tracking technology, proprietary algorithms, machine learning, cloud-based, Wi-Fi enabled, collects over 100,000 data points from eye movements, generates 'BOX score'
FDA Clearances5 cleared products (estimated)

What Physicians Need to Know

Concussion Diagnosis
Oculogica specializes in aiding the diagnosis of concussion using its FDA-cleared EyeBOXu00ae device. It objectively measures abnormalities in eye movements to detect concussions, providing a quantifiable 'BOX score' and eye-tracking metrics. The test is non-invasive, takes less than 4 minutes, and does not require a pre-injury baseline.
Traumatic Brain Injury (TBI) Detection
The EyeBOX technology is cleared as an aid in the diagnosis of mild traumatic brain injury (mTBI). Oculogica is also developing its eye-tracking technology for the early diagnosis of other forms of TBI.
Eye-Tracking Technology
At its core, Oculogica leverages advanced eye-tracking technology. The EyeBOX system uses an infrared illumination camera to capture over 100,000 data points of subtle eye movements and cranial nerve function at 500 frames per second. This data is then analyzed by proprietary algorithms.
Neurodiagnostics
As a neurodiagnostic company, Oculogica provides objective insights into neurological health. Their EyeBOX assesses cranial nerve control of eye movements, which can be impacted by brain injuries, offering a data-driven approach to neurological assessment.
Objective Neurological Assessment
Oculogica's EyeBOX moves beyond subjective symptom reporting by providing an objective, quantifiable assessment of brain function. It delivers an immediate 'BOX score' and detailed eye-tracking metrics, enhancing diagnostic accuracy and consistency.
Physician Tip

For physicians, Oculogica's EyeBOX offers a critical advancement in concussion care by providing an objective, rapid, and baseline-free diagnostic aid. Utilize its quantitative 'BOX score' and eye-tracking metrics to supplement your clinical judgment, especially in acute settings where subjective assessments can be challenging or unreliable. The ability to monitor recovery over time against normative data is invaluable for guiding return-to-activity decisions and tailoring rehabilitation plans. Its broad age range and language independence make it a versatile tool across diverse patient populations. Remember that EyeBOX is an *aid* in diagnosis and should be used in conjunction with a comprehensive neurological assessment.

While Oculogica's EyeBOX operates as an integrated system with its own display and computer for analysis, explicit details regarding direct integrations with Electronic Medical Records (EMR) or Electronic Health Records (EHR) systems via APIs or other interfaces are not extensively detailed in the publicly available information. The device generates a report, which would typically be manually or semi-automatically incorporated into a patient's record. Further inquiry with Oculogica would be necessary to understand specific integration capabilities.

Products by Oculogica

1 product in the directory

EyeBOX
Oculogica
Clinical Decision Support & Reference
EyeBOX by Oculogica is the first FDA-cleared, AI-powered eye-tracking device for objective, baseline-free concussion diagnosis and recovery monitoring in patients aged 5-67, delivering results in under 4 minutes.

What the Web Says

Oculogica is a company that develops FDA-cleared eye-tracking tools, EyeBOX and SNAP, for objective concussion diagnosis and rapid sideline screening. The products are praised for providing objective data, ease of use, and speed in assessing traumatic brain injury (TBI) status. While there is strong positive feedback regarding the product's capabilities, information on company culture or employer reviews for Oculogica specifically is not readily available on the searched platforms. Some reviews for similarly named companies (Ocular, Ocular Therapeutix, Logica North America, Oculoplastic Associates of Texas) were found, but these are distinct entities.

Overall: Positive

Strengths

  • Provides objective data for concussion diagnosis, reducing reliance on subjective symptom checklists.
  • EyeBOX and SNAP are FDA-cleared tools.
  • Fast assessment times (4-minute for EyeBOX, 90-second for SNAP).
  • Baseline-independent, eliminating the need for pre-injury baseline tests.
  • Child-friendly and easy to use.
  • Aids in tracking recovery and assessing therapeutic options.

Limitations

  • Limited information available on company/employer reviews for Oculogica specifically.
  • EyeBOX is an aid to diagnosis, not a standalone diagnostic tool.
  • Effectiveness of EyeBOX beyond one week after injury has insufficient evidence.
  • Not established for patients with moderate or severe TBI, or those with certain pre-existing conditions affecting eye movement or visual acuity.
  • A 2025 study found reduced sensitivity for the EyeBOX platform in a sport-related concussion population compared to earlier emergency-department cohorts.

Based on reviews from: Oculogica, Forbes, AAFP

Last updated: 2026-07-18

Videos

News, demos, and interviews about Oculogica.

Loading videos...

Videos load interactively. If none appear, search YouTube for Oculogica →

View all on YouTube

Press & Coverage

Oculogica
First 90-second sideline concussion test cleared by FDA
Oculogica Inc. announced on June 5, 2026, that the FDA granted 510(k) clearance for its SNAP Concussion Testu00ae, a 90-second sideline concussion test that combines eye tracking with symptom severity for a multi-modal assessment. SNAP diagnoses concussion with 90% sensitivity and 94% specificity, making it the highest accuracy concussion test cleared by the FDA.
2026-06
Neurofounders
Oculogica Brings Eye-Tracking Concussion Assessment to the Sideline
Oculogica received FDA 510(k) clearance for SNAP, a portable, infrared eye-tracking assessment tool that measures eye movements during a short visual task and combines these with self-reported symptom severity. The 90-second test does not require a pre-injury baseline and is designed for sideline and clinical settings.
2026-06
ProductDocket
FDA Clears Oculogica EyeBOX SNAP (K254086)
The FDA cleared Oculogica's EyeBOX SNAP on June 5, 2026, under 510(k) number K254086. This Class II neurology device is classified as a brain-injury adjunctive interpretive oculomotor assessment aid, analyzing eye movements to help clinicians evaluate suspected concussions.
2026-06
Med-Tech News
Oculogica Receives FDA Clearance for 90-Second SNAP Concussion Test
Oculogica announced FDA 510(k) clearance for its SNAP concussion test, a non-invasive diagnostic tool that assesses concussion in 90 seconds by combining eye-tracking technology with symptom severity. The test boasts 90% sensitivity and 94% specificity, making it a highly accurate FDA-cleared assessment tool.
2026-06
MassDevice
Oculogica wins FDA clearance for 90-second concussion test
Oculogica received FDA 510(k) clearance for its SNAP concussion test, a 90-second diagnostic that combines eye tracking with symptom severity for a multi-modal concussion assessment. The test can be used indoors or outdoors and has a high accuracy rate for diagnosing concussions.
2026-06
PR Newswire
Oculogica Announces Launch of New EyeBOXu00ae Device
Oculogica launched its new EyeBOX device on March 1, 2022, following FDA clearance earlier that year. The updated EyeBOX is lightweight, battery-operated, and portable, designed for easy use in both clinical and sports settings as the first objective diagnostic cleared by the FDA to aid in concussion diagnosis.
2022-03
Oculogica
Oculogica Receives Department of Defense Grant to Develop Wearable Concussion Diagnostic with Pre-eminent Partners
Oculogica announced on May 17, 2021, that it received a $2 million grant from the U.S. Army Medical Research and Development Command (USAMRDC) to develop a wearable version of its concussion diagnostic technology. This grant aims to significantly advance medical technology for assessing mild traumatic brain injury in various settings.
2021-05
PR Newswire
Australia's TGA Grants Approval to First Objective Concussion Diagnostic
Oculogica, Inc. announced on May 4, 2021, that the Therapeutic Goods Administration (TGA) of Australia approved its EyeBOXu00ae, making it the first baseline-free tool to aid in concussion diagnosis in Australia. The EyeBOX uses eye-tracking to provide objective information for assessing suspected concussions in both pediatric and adult patients.
2021-05

Frequently Asked Questions

Oculogica's EyeBOX is an FDA-cleared, non-invasive device that uses eye-tracking technology to objectively aid in the diagnosis of concussion (mild traumatic brain injury) by measuring abnormalities in eye movements. The device collects over 100,000 data points during a short video, generating a 'BOX score' that indicates the likelihood of concussion without requiring a pre-injury baseline test. It is intended for use in conjunction with a standard neurological assessment for patients aged 5-67.
The EyeBOX offers an objective, baseline-free assessment that takes less than four minutes to complete, providing immediate results to aid in diagnosis and monitor recovery. Its non-invasive nature and broad age range (5-67) make it suitable for diverse patient populations, including those who may be disoriented or nonverbal. The device's portability and battery operation also allow for use in various clinical and even far-forward settings.
Oculogica's EyeBOX is FDA-cleared, having received its initial de novo authorization in 2018 as the first device of its kind. The company has since obtained multiple 510(k) clearances, including an expanded label in April 2025, which broadens its utility for interpreting test results, tracking patient recovery, and supporting therapeutic interventions. It is also registered with Health Canada.
While specific pricing is not publicly disclosed, Oculogica aims to make the EyeBOX accessible and cash-flow positive for clinics. The EyeBOX test is reimbursable and has an established CPT code, though reimbursement may depend on specific payor contracts and require prior authorization. Oculogica also provides training to medical professionals on how to interpret the BOX score and offers demos for clinical practices.
Oculogica, founded by neurosurgeon Dr. Uzma Samadani, has demonstrated stability through significant funding, including an $8 million Series A round led by TitletownTech (a venture fund by the Green Bay Packers and Microsoft). The company is actively moving towards full commercialization and has partnerships with institutions like Keller Army Hospital at West Point and Children's Hospital of Philadelphia for developing future technologies, such as a wearable diagnostic.
Yes, Oculogica is expanding its intellectual property portfolio beyond concussion diagnosis. The company has received a patent for assessing glaucoma using its non-invasive eye-tracking system, indicating potential future product development in other neurological and ophthalmic conditions. They are also involved in studies assessing applications in specific, emerging concussion therapies and other neurological conditions like elevated intracranial pressure.

Investors

Who's funded Oculogica.

Related Companies

e4health is a healthcare consulting and services company that provides innovative solutions to hospitals, health systems, outpatient providers, and physician practices. The company focuses on addressing data, quality, and revenue challenges within the healthcare ecosystem. Their services are designed to streamline health information data and workflows, optimize coding, quality, and clinical documentation integrity processes, and […]

PayZen is a healthcare fintech company that leverages AI and automation to address the growing challenge of healthcare affordability for patients and financial stability for providers. The platform offers personalized, interest-free payment plans, extending up to 60 months, tailored to each patient’s ability to pay. This approach aims to remove financial barriers to care, allowing […]

Healthcare Finance.AI is dedicated to optimizing healthcare revenue cycles through cutting-edge AI technologies. The company aims to improve financial outcomes for healthcare providers while supporting their commitment to quality care and efficiency. Their solutions are designed to enhance revenue cycle efficiency, reduce claim turnaround times, and improve patient billing accuracy. Their platform leverages advanced analytics […]

The American Academy of Family Physicians (AAFP) is one of the largest national medical organizations in the United States, representing over 130,000 family physicians, residents, and medical students. Founded in 1947, its core mission is to improve the health of patients, families, and communities by serving the needs of its members with professionalism and creativity. […]

Imperial College Business School, a faculty of Imperial College London, is a leading institution that integrates business education with science, engineering, medicine, and technology. For physicians and healthcare providers, the Business School offers specialized programs and research focused on the intersection of AI, digital transformation, and healthcare management. Their curriculum is designed to equip healthcare […]

Columbia University, through its online learning platform edX, offers a range of educational programs, including those focused on artificial intelligence and its applications in healthcare. While not a direct AI product company, Columbia University provides foundational and advanced courses that equip physicians and healthcare providers with the knowledge and skills to understand, evaluate, and potentially […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.